Baraclude gives off its throne in 7 years, continued by Viread

No throne can last forever.

‘Baraclude,’ which has kept its top position for 7 consecutive years in the hepatitis B therapy market since 2011, has been weakened due to aggressive attacks of generics since October last year.

According to the analysis result of the 2016 1^st half’s prescription records based on the pharmaceutical market research institute, UBIST, on the 26^th, Baraclude recorde...